294 related articles for article (PubMed ID: 6460216)
1. Mechanisms of immunity in cancer.
Baldwin RW
Pathobiol Annu; 1981; 11():155-75. PubMed ID: 6460216
[No Abstract] [Full Text] [Related]
2. [Monoclonal antibodies and cancer].
López González JS; Selman Lama M
Salud Publica Mex; 1985; 27(3):213-34. PubMed ID: 2996157
[No Abstract] [Full Text] [Related]
3. Immunological monitoring of renal allograft recipients using monoclonal antibodies to human T lymphocyte subpopulations.
Ellis TM; Berry CR; Mendez-Picon G; Goldman MH; Lower RR; Lee HM; Mohanakumar T
Transplantation; 1982 Mar; 33(3):317-9. PubMed ID: 6461117
[No Abstract] [Full Text] [Related]
4. An introduction to tumour immunology.
James K
Arch Immunol Ther Exp (Warsz); 1983; 31(6):795-808. PubMed ID: 6611141
[TBL] [Abstract][Full Text] [Related]
5. The gordian knot of tumour immunology.
Amlot P
Guys Hosp Rep; 1974; 123(1):43-51. PubMed ID: 4549511
[No Abstract] [Full Text] [Related]
6. Human monoclonal antibodies.
Kan-Mitchell J; Mitchell MS
Prog Clin Biol Res; 1989; 288():85-94. PubMed ID: 2717643
[No Abstract] [Full Text] [Related]
7. Effector immune mechanisms in cancer.
Lotzová E
Nat Immun Cell Growth Regul; 1985; 4(6):293-304. PubMed ID: 3911064
[No Abstract] [Full Text] [Related]
8. Tumor-associated glycolipid antigens defined by monoclonal antibodies.
Hakomori S
Bull Cancer; 1983; 70(2):118-26. PubMed ID: 6191806
[TBL] [Abstract][Full Text] [Related]
9. [Immunology and cancer].
Brunner KT
Schweiz Med Wochenschr; 1973 Sep; 103(36):1249-52. PubMed ID: 4584090
[No Abstract] [Full Text] [Related]
10. Immunologic problems and perspectives in the therapeutic use of monoclonal antibodies in nephrology.
Bach JF; Chatenoud L
Adv Nephrol Necker Hosp; 1985; 14():365-88. PubMed ID: 3919539
[No Abstract] [Full Text] [Related]
11. Isolation of isotype variants from hybridomas producing monoclonal antibodies to urothelial cancer associated antigens.
Lovric J; Decken K; Ebert T; Schmitz-Dräger BJ
Investig Urol (Berl); 1994; 5():71-5. PubMed ID: 7719324
[No Abstract] [Full Text] [Related]
12. Production of anti-tumor human monoclonal antibodies using different approaches.
Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
[TBL] [Abstract][Full Text] [Related]
13. Analysis of hybridoma-exchange antibodies.
Lloyd KO; Albino A; Houghton A
Hybridoma; 1982; 1(4):461-3. PubMed ID: 6208140
[No Abstract] [Full Text] [Related]
14. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
15. Antimelanoma hybridoma antibodies against partially purified melanoma antigen.
Medrano L; Cesarini JP; Daveau M; Phillips J; Salazar G; Fontaine M; Phillips T; Viza D; Prunieras M
Eur J Cancer Clin Oncol; 1983 Feb; 19(2):153-61. PubMed ID: 6337853
[TBL] [Abstract][Full Text] [Related]
16. The optimal technological approach to the development of human hybridomas.
Dorfman NA
J Biol Response Mod; 1985 Jun; 4(3):213-39. PubMed ID: 2991473
[No Abstract] [Full Text] [Related]
17. Immunology in tumor therapeutics: an overview.
Barber HR
Del Med J; 1980 Apr; 52(4):197-209. PubMed ID: 6153996
[No Abstract] [Full Text] [Related]
18. [New aspects of tumor immunology. Importance of the T-cell system].
Knuth A; Dippold W; Meyer zum Büschenfelde KH
Dtsch Med Wochenschr; 1982 Jul; 107(28):1105-10. PubMed ID: 6177489
[No Abstract] [Full Text] [Related]
19. Some immunological considerations relevant to the study of human bladder cancer.
Bean MA
Cancer Res; 1977 Aug; 37(8 Pt 2):2879-84. PubMed ID: 326394
[TBL] [Abstract][Full Text] [Related]
20. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
[No Abstract] [Full Text] [Related]
[Next] [New Search]
